The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy (DCOECRT)
Primary Purpose
Stage III Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Status
Unknown status
Phase
Phase 3
Locations
China
Study Type
Interventional
Intervention
Capecitabine(Aibin)
Oxaliplatin(Aiheng)
Radiotherapy
Sponsored by
About this trial
This is an interventional treatment trial for Stage III Esophageal Squamous Cell Carcinoma focused on measuring Chemoradiotherapy, Esophageal Squamous Cancer, Capecitabine and oxaliplatin, Chinese, Randomized Controlled Trials
Eligibility Criteria
Inclusion Criteria:
- Voluntary participation and signed a consent form
- Histologically proven squamous cell carcinoma of the esophagus, initial treatment (Not had surgery, radiotherapy, chemotherapy or targeted therapy)
- the tumor was in T2-4N0-2M0, locally advanced(AJCC2002)
- Have a measurable lesions.
- Male or female who has fertility is willing to take contraceptive measures in the experiment
- WBC≥3x10 9/L;Hb≥80g/L;ANC ≥1.5x10 9/L;PLT ≥100x10 9/L;TBIL< 1.5xN;AST (SGOT)/ALT (SGPT) ≤2.5xN;Cr≤1.5xN.
- Performance status score 0-2
- Expected lifetime>3 months
Exclusion Criteria:
- Pregnant, lactating women or With fertility but did not use contraceptive measures
- Has a history of severe allergic or idiosyncrasy
- Hab been treated with surgery, radiation and chemotherapy or targeted therapy for esophageal cancer
- After exploratory thoracotomy or Laying an esophageal tracheal stent
- Received a major surgery treatment within 28 days prior to the start of research and treatment
- History of organ transplantation
- Has uncontrolled seizures or Lose self-knowledge because of mental illness
- Severe infection
- Oral capecitabine who have difficulty with,such as esophageal obstructed completely, dysphagia,The activities of digestive ulcer, Gastrointestinal bleeding
- Severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,high blood pressure, diabetes.
- Other malignant tumor in recent 5 years.
Sites / Locations
- The First Affiliated Hospital of Henan University of Science and TechnologyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Capecitabine-oxaliplatin 2 cycles
Capecitabine-oxaliplatin 4 cycles
Arm Description
oxaliplatin:65mg/m2,d1,8,22,29,I.V; capecitabine: 625mg/m2, bid d1-5; q1w, po,5 weeks in total; radiotherapy:50Gy,2 Gy/d,5d/w.
oxaliplatin:65mg/m2,d1,8,22, 29,43,50,64,71,I.V; capecitabine:625mg/m2,bid d1-5; q1w, po,10 weeks in total; radiotherapy:50Gy ,2 Gy/d,5d/w.
Outcomes
Primary Outcome Measures
overall survival, OS
Secondary Outcome Measures
progression-free survival,PFS
overall remission rate, ORR
serious adverse event,SAE
quality of life, Qol
pathologic complete response rate
disease control rate,DCR
Full Information
NCT ID
NCT02604615
First Posted
November 11, 2015
Last Updated
July 2, 2016
Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Collaborators
The First Affiliated Hospital of Zhengzhou University, Xinyang Central Hospital, Anyang Tumor Hospital, No. 150 Central Hospital of the Chinese People Liberation Army
1. Study Identification
Unique Protocol Identification Number
NCT02604615
Brief Title
The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy
Acronym
DCOECRT
Official Title
Two Cycles Versus Four Cycles of Capecitabine Combined Oxaliplatin Concurrent Radiotherapy as First-line Therapy for Chinese Locally Advanced Esophageal Squamous Cell Carcinomas, an Open Randomised Phase III Cilinical Trial
Study Type
Interventional
2. Study Status
Record Verification Date
July 2016
Overall Recruitment Status
Unknown status
Study Start Date
October 2014 (undefined)
Primary Completion Date
December 2017 (Anticipated)
Study Completion Date
December 2020 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Collaborators
The First Affiliated Hospital of Zhengzhou University, Xinyang Central Hospital, Anyang Tumor Hospital, No. 150 Central Hospital of the Chinese People Liberation Army
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
A two-arm (two cycles' versus four cycles' capecitabine combined oxaliplatin concurrent radiotherapy) randomised Phase III clinical trial was started in Oct. 2015. Definitive chemoradiotherapy is the standard regimen in Western countries for patients with esophageal cancer who can't receive surgery or reject surgery. But in China because of its severer toxic reaction, most of patients had to discontinue treatment at the halfway way. Thus, the chemotherapy regimen of capecitabine combined oxaliplatin are widely used in clinical due to its characristic of low toxic reaction.
The purpose of this study is to confirm the efficacy and safety of the different cycles(two cycles and four cycles ) of Capecitabine-oxaliplatin in Chinese esophageal squamous carcinoma radical concurrent chemoradiotherapy. A total of 60 patients will be accrued from China within 2 years. The primary endpoint is overall survival and the secondary endpoints include progression-free survival, response rate, pathologic complete response rate and adverse events.
Detailed Description
First: The investigators use excel generate a 5 digits random number table. After subjects sign the informed consent, investigators will chose one for themm. Subject who get an odd number will receive 2cycles' chemotheapy concurrent radiotherapy and even number receive 4cycles'. Investigators should record the congruent relationship of subjects with group code.
Second: The investigators are required to record subjects' base measurements. The base measurements items:1.Tumor confirmed date,TNM staging,History of esophageal cancer treatment;2.Demographic data,past medical history;3.physical examination(a detailed system check including general neurological examination);4.vital signs,Height,Weight;5.PS score,Quality of life;6.serum biochemistry(ALT,AST,AKP,TBIL,blood glucose,BUN,Ccr,electrolyte,et al.);7. Blood RT(RBC,HGB,WBC,ANC,PLT,et al.);8.Urine routines;9.Endoscopic biopsy(More than 3 pieces of biopsy specimens),chest CT,abdomen ultrasound/CT/MRI,PET-CT,et al.;10.Blood/urine pregnancy tests;11.Collect blood samples(5 ml);12.Preserve CorpseSample. note:Check the time limit-2 weeks before get into groups.
Third:Observation items during treatment include 3-8 items of the base measurements;Radiotherapy 20 times, should review of esophageal barium meal or chest CT. The investigators need to observe adverse event during treatment and eveluate the relationship of adverse event with researched therapeutic regimen according to the Common Terminology Criteria for Adverse Events,CTCAE) (V4.0, 2009-05-28) and accurately fill in Case Report Form(CRF).
Fourth: Follow-up items include 3-9 items of the base measurements;bood and tissue sample should also be preserved when subject receives 16th weeks' review.
The patient who withdrew from the study during researched treatment must accept the end evaluation research. The investigators must record the reason and the date of termination in patient' progress note and CRF.
Cases of complete report should transfer to data administrators after investigates by clinical research associate. Data administrators input and management data.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Stage III Esophageal Squamous Cell Carcinoma, Esophageal Neoplasms
Keywords
Chemoradiotherapy, Esophageal Squamous Cancer, Capecitabine and oxaliplatin, Chinese, Randomized Controlled Trials
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Capecitabine-oxaliplatin 2 cycles
Arm Type
Experimental
Arm Description
oxaliplatin:65mg/m2,d1,8,22,29,I.V; capecitabine: 625mg/m2, bid d1-5; q1w, po,5 weeks in total; radiotherapy:50Gy,2 Gy/d,5d/w.
Arm Title
Capecitabine-oxaliplatin 4 cycles
Arm Type
Active Comparator
Arm Description
oxaliplatin:65mg/m2,d1,8,22, 29,43,50,64,71,I.V; capecitabine:625mg/m2,bid d1-5; q1w, po,10 weeks in total; radiotherapy:50Gy ,2 Gy/d,5d/w.
Intervention Type
Drug
Intervention Name(s)
Capecitabine(Aibin)
Other Intervention Name(s)
Aibin
Intervention Description
capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
Intervention Type
Drug
Intervention Name(s)
Oxaliplatin(Aiheng)
Other Intervention Name(s)
Aiheng
Intervention Description
Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
Intervention Type
Radiation
Intervention Name(s)
Radiotherapy
Other Intervention Name(s)
Radiation Therapy
Intervention Description
concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
Primary Outcome Measure Information:
Title
overall survival, OS
Time Frame
2 years
Secondary Outcome Measure Information:
Title
progression-free survival,PFS
Time Frame
2 years
Title
overall remission rate, ORR
Time Frame
16 weeks
Title
serious adverse event,SAE
Time Frame
16 weeks
Title
quality of life, Qol
Time Frame
16 weeks
Title
pathologic complete response rate
Time Frame
16 weeks
Title
disease control rate,DCR
Time Frame
16 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
45 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Voluntary participation and signed a consent form
Histologically proven squamous cell carcinoma of the esophagus, initial treatment (Not had surgery, radiotherapy, chemotherapy or targeted therapy)
the tumor was in T2-4N0-2M0, locally advanced(AJCC2002)
Have a measurable lesions.
Male or female who has fertility is willing to take contraceptive measures in the experiment
WBC≥3x10 9/L;Hb≥80g/L;ANC ≥1.5x10 9/L;PLT ≥100x10 9/L;TBIL< 1.5xN;AST (SGOT)/ALT (SGPT) ≤2.5xN;Cr≤1.5xN.
Performance status score 0-2
Expected lifetime>3 months
Exclusion Criteria:
Pregnant, lactating women or With fertility but did not use contraceptive measures
Has a history of severe allergic or idiosyncrasy
Hab been treated with surgery, radiation and chemotherapy or targeted therapy for esophageal cancer
After exploratory thoracotomy or Laying an esophageal tracheal stent
Received a major surgery treatment within 28 days prior to the start of research and treatment
History of organ transplantation
Has uncontrolled seizures or Lose self-knowledge because of mental illness
Severe infection
Oral capecitabine who have difficulty with,such as esophageal obstructed completely, dysphagia,The activities of digestive ulcer, Gastrointestinal bleeding
Severe chronic diseases, such as, hepatopathy, nephropathy, respiratory disease,high blood pressure, diabetes.
Other malignant tumor in recent 5 years.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shegan Gao, Doctor
Phone
18638859977
Email
gsg112258@163.com
First Name & Middle Initial & Last Name or Official Title & Degree
Tanyou Shan, Master
Phone
18537976669
Email
shantanyou@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shegan Gao, Doctor
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Tanyou Shan, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Xiaoshan Feng, Doctor
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Jiachun Sun, Doctor
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xinshuai Wang, Doctor
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Guoqiang Kong, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xiaozhi Yuan, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ruinuo Jia, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dan Zhou, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jing Ren, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ruina Yang, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dan Wang, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yongxuan Liu, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yali Zhang, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Weijiao Yin, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Wei Wang, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Shiyuan Song, Master
Organizational Affiliation
The First Affiliated Hospital of Henan University of Science and Technology
Official's Role
Principal Investigator
Facility Information:
Facility Name
The First Affiliated Hospital of Henan University of Science and Technology
City
Luoyang
State/Province
Henan
ZIP/Postal Code
471003
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
shegan gao, doctor
Phone
0379 64811906
Email
gsg112258@163.com
First Name & Middle Initial & Last Name & Degree
tanyou shan, master
Phone
0379 64815350
Email
shantanyou@163.com
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
20888705
Citation
Park JW, Kim JH, Choi EK, Lee SW, Yoon SM, Song SY, Lee YS, Kim SB, Park SI, Ahn SD. Prognosis of esophageal cancer patients with pathologic complete response after preoperative concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):691-7. doi: 10.1016/j.ijrobp.2010.06.041. Epub 2010 Oct 1.
Results Reference
background
PubMed Identifier
24737541
Citation
Fakhrian K, Ordu AD, Haller B, Theisen J, Lordick F, Bisof V, Molls M, Geinitz H. Cisplatin- vs. oxaliplatin-based radiosensitizing chemotherapy for squamous cell carcinoma of the esophagus: a comparison of two preoperative radiochemotherapy regimens. Strahlenther Onkol. 2014 Oct;190(11):987-92. doi: 10.1007/s00066-014-0661-x. Epub 2014 Apr 16.
Results Reference
background
PubMed Identifier
21652581
Citation
Pera M, Gallego R, Montagut C, Martin-Richard M, Iglesias M, Conill C, Reig A, Balague C, Petriz L, Momblan D, Bellmunt J, Maurel J. Phase II trial of preoperative chemoradiotherapy with oxaliplatin, cisplatin, and 5-FU in locally advanced esophageal and gastric cancer. Ann Oncol. 2012 Mar;23(3):664-670. doi: 10.1093/annonc/mdr291. Epub 2011 Jun 7.
Results Reference
background
PubMed Identifier
19230050
Citation
Qin TJ, An GL, Zhao XH, Tian F, Li XH, Lian JW, Pan BR, Gu SZ. Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World J Gastroenterol. 2009 Feb 21;15(7):871-6. doi: 10.3748/wjg.15.871.
Results Reference
background
PubMed Identifier
18825381
Citation
Chiarion-Sileni V, Innocente R, Cavina R, Ruol A, Corti L, Pigozzo J, Del Bianco P, Fumagalli U, Santoro A, Ancona E. Multi-center phase II trial of chemo-radiotherapy with 5-fluorouracil, leucovorin and oxaliplatin in locally advanced esophageal cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1111-9. doi: 10.1007/s00280-008-0834-3. Epub 2008 Sep 30.
Results Reference
background
PubMed Identifier
17476140
Citation
O'Connor BM, Chadha MK, Pande A, Lombardo JC, Nwogu CE, Nava HR, Yang G, Javle MM. Concurrent oxaliplatin, 5-fluorouracil, and radiotherapy in the treatment of locally advanced esophageal carcinoma. Cancer J. 2007 Mar-Apr;13(2):119-24. doi: 10.1097/PPO.0b013e318046ee1a.
Results Reference
background
PubMed Identifier
26468007
Citation
Lee SJ, Kim S, Kim M, Lee J, Park YH, Im YH, Park SH. Capecitabine in combination with either cisplatin or weekly paclitaxel as a first-line treatment for metastatic esophageal squamous cell carcinoma: a randomized phase II study. BMC Cancer. 2015 Oct 14;15:693. doi: 10.1186/s12885-015-1716-9.
Results Reference
background
PubMed Identifier
24578238
Citation
Xing L, Liang Y, Zhang J, Wu P, Xu D, Liu F, Yu X, Jiang Z, Song X, Zang Q, Wang W. Definitive chemoradiotherapy with capecitabine and cisplatin for elder patients with locally advanced squamous cell esophageal cancer. J Cancer Res Clin Oncol. 2014 May;140(5):867-72. doi: 10.1007/s00432-014-1615-5. Epub 2014 Mar 1.
Results Reference
background
PubMed Identifier
21968953
Citation
Koo DH, Park SI, Kim YH, Kim JH, Jung HY, Lee GH, Choi KD, Song HJ, Song HY, Shin JH, Cho KJ, Yoon DH, Kim SB. Phase II study of use of a single cycle of induction chemotherapy and concurrent chemoradiotherapy containing capecitabine/cisplatin followed by surgery for patients with resectable esophageal squamous cell carcinoma: long-term follow-up data. Cancer Chemother Pharmacol. 2012 Mar;69(3):655-63. doi: 10.1007/s00280-011-1750-5. Epub 2011 Oct 4.
Results Reference
background
PubMed Identifier
19270824
Citation
Lee SJ, Ahn BM, Kim JG, Sohn SK, Chae YS, Moon JH, Lee EB, Kim JC, Park IK, Jeon SW. Definitive chemoradiotherapy with capecitabine and cisplatin in patients with esophageal cancer: a pilot study. J Korean Med Sci. 2009 Feb;24(1):120-5. doi: 10.3346/jkms.2009.24.1.120. Epub 2009 Feb 28.
Results Reference
background
PubMed Identifier
17762932
Citation
Lee J, Im YH, Cho EY, Hong YS, Lee HR, Kim HS, Kim MJ, Kim K, Kang WK, Park K, Shim YM. A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. Cancer Chemother Pharmacol. 2008 Jun;62(1):77-84. doi: 10.1007/s00280-007-0577-6. Epub 2007 Aug 31.
Results Reference
background
Learn more about this trial
The Role of Different Cycles of Chemotherapy(Capecitabine-oxaliplatin) in Esophageal Chemoradiotherapy
We'll reach out to this number within 24 hrs